cd8+nkg2d+ akt cell
Cell therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2016 (NCT02929797)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- NKG2-D type II integral membrane proteinImmunity, passive
immunity, passive - KLRK1
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- akt
- cd8+nkg2d+ akt cell
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02929797 | Early Phase 1 (Phase 1) | Aug 1, 2016 | Jiao Tong University, Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiao Tong University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China | For profit | 1 | 0 | 1 | 2016 |
2 organizations
Page 1 / 1